YHEC attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress in Amsterdam 10th-12th November 2014. Read about some of YHEC’s research presentations below.
Monday 10th November
Matthew Taylor delivers a podium presentation on the consequences of using alternative methods for the derivation and extrapolation of survival data drawn from published Kaplan-Meier curves.
Tuesday 11th November
Matthew Taylor and Joyce Craig evaluate the clinical and cost-effectiveness and budget impact of routine use of Bispectral Index Monitors in operating theatres.
Adam Smith and Matthew Taylor evaluate the internal reliability of the EORTC QLQ-BR23 – a patient-reported outcome (PRO) measure used in oncology – through reliability generalisation, a meta-analytic technique for pooling Cronbach’s alpha coefficients.
Matthew Taylor and Alex Filby discuss the impact of survival costs in oncology modelling, with a focus on what factors determine if a drug can be cost-effective.
Mick Arber, Hannah Wood and Julie Glanville investigate the quality of search methodology and search reporting in published systematic reviews of economic evaluations; focusing on how the choice of resources to search for evidence reflects current recommendations for the conduct of such reviews.
Adam Smith evaluates whether the measurement properties of the EuroQol (EQ) 5D hold across different surgical interventions, and whether the continued use of the instrument to draw comparisons across different health conditions is warranted.
Robert Hodgson and Lindsay Claxton compare the use of Markov and patient simulation models in the context of a degenerative ophthalmological condition.
Wednesday 12th November
Matthew Taylor presents the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2-negative advanced and metastatic breast cancer in postmenopausal women in Kazakhstan.
Julie Glanville and Matthew Taylor evaluate the cost-effectiveness of Everolimus plus Exemestane compared to chemotherapy agents for the treatment of ER+ HER2- metastatic breast cancer in the United Kingdom. Matthew also discusses treatment options Everolimus plus Exemestane compared to Exemestane and Fulvestrant.